Hence, calculating BCR-ABL1 HTs may prove of clinical value to rapidly recognize CML patients that are likely to achieve deep molecular responses on IM. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.